8-lower alkoxyisoquinolinium halides

ABSTRACT

NOVEL PHARMACOLOGICALLY ACTIVE 8-(LOWER ALKOXY)-1,2, 3,4-TETRAHYDROISOQUINOLINES, 8-(LOWER ALKOXY)-1 AND/OR 2-(LOWER ALKYL)-1,2,3,4-TETRAHYDROISOQUINOLINES AND INTERMEDIATES THEREFOR, ARE PREPARED UTILIZING, FOR EXAMPLE, 8ISOQUINOLINOL AS A STARTING MATERIAL. THE PHARMACOLOGICALLY ACTIVE COMPOUNDS OF THE INVENTION ARE USEFUL AS HYPOTENSIVE AGENTS.

United States PatentC ABSTRACT OF THE DISCLOSURE Novel pharmacologically active 8-(l0wer alkoxy)-l,2, 3,4-tetrahydroisoquinolines, 8-(lower alkoxy)-1 and/or 2-(lower alkyl)-1,2,3,4-tetrahydroisoquinolines and intermediates therefor, are prepared utilizing, for example, 8- isoquinolinol as a starting material. The pharmacologically active compounds of the invention are useful as hypotensive agents.

CROSS-REFERENCE TO RELATED APPLroAnoNs This application is a division of US. patentapplication Ser. N0. 664,269, filed Aug. 30, 1967 and issued on Feb. 9, 1971 as US. Pat. No. 3,562,280.

BRIEF SUMMARY OF THE INVENTION In one aspect, the invention relates to substituted isoquinolinium compounds of the formula wherein R is lower alkyl and X- is selected from the group consisting of iodine, chlorine and bromine.

In another aspect, the invention relates to compounds of the formula Br I I wherein R is lower alkyl, R, is selected from the group consisting of .lower alkyl and benzyl, andXT-is selected from the group consisting of chlorine, bromine and iodine.- 1

In still another aspect, the invention relates to compounds of the formula wherein R; is lower alkyl.

The foregoing compounds are useful in the preparation of substituted 1,2,3,4-tetrahydroisoquinolines of the formula y 0mm I 3,661,913 Patented May 9, 1972 "ice wherein R is lower alkyl and R and R are hydrogen or lower alkyl,

and acid addition salts thereof with pharmaceuticallyac ceptable acids.- The compounds of the invention, i.e., the compound of Formula are useful as hypotensive agents. 'DETAILED DECRIPTIONOF THE INVENTION The invention relatesto pharmacologically activel 2,

3,4-tetrahydroisoquin0lines of the formula wherein is'lower alkyl R and R are independently selected from the group consisting of hydrogen and .b alkyh a a g and acid addition acceptable acids.

,,In aparticularly advantageous aspect, the invention relates'to the sub'genus characterized by the formula salts thereof with harmaceutical I 0134 18 wherein R and R are as previously described, and acid addition salts thereof with pharmaceutically acceptable acids.

In another aspect, the invention relates to the subgenus characterized by the formula wherein R is as previously described, .andR and R are lower alkyl,

and acid addition salts theerof with pharmaceutically acceptable acids.

In still another aspect, the invention relates to novel intermediates characterized by the formulas XII XIV wherein R is a previously described, X- is a halogen alkyl or benzyl.

such as chlorine, bromine or iodine, and R is lower As used herein, the term lower alkyl denotes a. straight or branched chain hydrocarbon group containing 1 -7 carbonatoms, e.g., methyl, ethyl, propyl, isopropyl, butyl, tertiary butyl and the like; methyl is preferred. The term lower alkoxy denotes a lower alkyl ether group additional salts ham L in which the lower alkyl moiety is as described above;

methoxy is preferred. i

7 Examples of the compounds of Formula I are:

lnitridacid,phosphoric acid, sulfuricacid and the like.

The compoundsof Formula I are prepared according i sodium hydroxide, to yield the corresponding compound to processes illustrated by the following reaction "schemes? Scheme I Prqflfl; .3 Process 3 OK In lower alkyl halide 1. alkali natal alkoxicle 2. elkylatin. agent;

/N-RL- OH x B X IV Reduction l/Reduction N-lowcr alkyl 0H ti-n;

lc lis u flcisl 860 cu V I if It:

(Juicer aikyl Id wherein R is as previously described, R, ishydrogen or lower alkyl, halide is iodide, chloride or bromide and X" is-iodine, chlorine or bromine.

Process A of Scheme I is carried out by reacting 8-isoquinolinol (III), a known compound, with an alkylating agent, such as methyl iodide, in the presence of an alkali metal alkoxide, such as sodium methylate, at a temperature in the range of from about to about 80 to form of Formula Id.

Scheme II Process 0 Process n t [Ce 5 o)a] Ra0 V Reduction I 5 I 0H I III /N vn OCH; Reduction NH N-CHO OCH; Ie H alkali 'alkyl halide metal alkoxid 0 3;, X I s mineral, acid a compound of Formula VI. A compound of Formula VI is then reduced utilizing, for example, sodium borohydride or hydrogen under pressure in the presence of platinum oxide, to form the corresponding compound of Formula Ic. Process B of Scheme I is carried out by reacting 8-isoquinolinol with a lower alkyl halide, such as methyl-iodide, 2

or a dialkyl sulfate, such as dimethyl sulfate, to yield a compound of Formula IV. A compound of Formula IV is then reduced, for example, with hydrogen under pressure in the presence of platinum oxide to formthe corresponding compound of Formula V. A compound of Formula V is reacted with phenyltrimethylammoniurn chloride in the presence of an alkali metal alkoxide,=such as sodium methoxide, or an alkali metal hydroxide, such as Process C of Scheme '11 is, carried out by reducing the 8-isoquinolinol, as previously described, to form the compound of Formula VIII. The compound of Formula VIII is reacted with formic acid and tertiary amine, such as triethylamine, to form the compound of Formula IX, whichis in turn reacted with analkylating agent, such as methyl-iodide, in the presence of an alkalimetal alkoxide',-'such as sodium 'rrie'thylate, to form a compound of Formula X. A compound of Formula X is treated with a mineral acid, such as hydrochloric or sulfuric acid, to form the corresponding compound, of Formula If.

Process D of Scheme II is carried out by reacting the 8-isoquinolinol with phenylt rimethylammonium chloride in the presence of an alkali metal 'alkoxide, such as sodium methoxide, or an alkali metal hydroxide, such as sodium hyd'roxidq'to yield the compound of Formula VII; The compound of Formula VII is reduced, for example, utiliz- -'in g'hydrogen-under pressure in the presence of platinum oxide to form the compound of Formula Ie.

- Scheme III l w N}! hypohalidc OR; OR; XI

lower alkyl halide lower alkyl agnesium halide 1 lower alkyl /ll-lcwer alkyl OR; lower alkyl. ORL

Ib I x1: :1 The reaction of Scheme III is carried out by reacting an 8-alkoxy-1,2,3,4-tetrahydroisoquinoline of Formula Elf Scheme IV m benzyl hang OR} I +1 li-C li1 DB; x

XII'n lower alkyl. magnesium halide c a; alygic debcnzylation QB; lower alkyl lower allcyl XIV Norepinephrine Histamine 8-methoxy-2-methyl tetrahydroisoquinoline minutes 30 minutes 60 minutes The reaction of Scheme IV is carried out by reacting acompound of Formula XI with a benzyl halide, such as benzyl bromide, to yield a compound of Formula XIIb.

A compound of Formula XIIb is then reacted with a lower alkyl magnesium halide, such as methyl magnesium iodide, to yield the corresponding compound of Formula XIV, whcih can be'catalytically debenzylated, for example by reacting with hydrogen in the presence of palladium on charcoal, to form the corresponding compound of Formula Ig. I

All the reactions described above may be conducted in the presence of added solvent such as methanol, methylcrease in peripheral vascular resistance without any substantial inhibition of the peripheral autonomic system and with only minimal blocking effects upon the adrenergic eifector sites. Moreover, the compounds of Formula I possess the advantage of being devoid of certain undesirable effects, for instance, they do not significantly increase the heart rate. Thus, the compounds of the invention are useful, for example, in the treatment of vascular diseases such as hypotension.

- The vasodilator and blood pressure reducing properties of the compounds of Formula I can be demonstrated in warm-bloded animals utilizing standard procedures, for example, in nembutalized dogs anesthetized, heparinized, and prepared for recording of the systemic, blood pressure and the pressure in a constant flow-perfused hind limb. In particular, blood from a cannulated carotid artery is passed by tube through a sigmomotor pump to a distally cannulated femoral artery. The pressure between the constant flow pump and the hind limb is monitored throughout the study. Changes in the vascular resistance result in changes in the perfusion pressure. Control responses to intravenously injected norepinephrine and histamine are obtained and the test drug is administered intravenously at 4.0 mg./kg.

TABLE I Dog No. 1 Dog No. 2

Average perfusion pressure predose Perfusion pressure change 13.1. P., change, mm. Hg

Duration, minutes Duration, minutes For use as hypotensive agents, the novel compounds of Formula I are formulated, using conventional inert pharmaceutical adjuvant materials, into dosage forms which are suitable for oral or parenteral administration. Such dosage forms include tablets, suspensions, solutions, etc. Furthermore, the compounds of this invention can be embodied into, and administered in the form of, suitable hard or soft capsules. The identity of the inert adjuvant materials which are used in formulating the present compounds into oral and parenteral dosage forms will be immedimula I base or an equivalent amount of a medicinally acceptable acid addition salt thereof. For parenteral administration, it is preferred to provide a solution containing from about 1 mg./ml. to about mg./ml. of the Formula I base, or an equivalent quantity of a salt thereof.

The frequency with which any such dosage form will be administered to a warm-blooded animal will vary, depending upon the quantity of active medicament present therein and the needs and requirements of the warmblooded animal, as diagnosed by the prescribing practitioner. Under ordinary circumstances, however, up to about 250 mg./kg. of the compound can be administered daily in several oral doses. It is to be understood, however, that the dosages set forth therein are exemplary only and that they do not, to any extent, limit the scope or practice of this invention.

The following non-limiting examples further illustrate the invention. All parts are by weight and all temperatures are in degrees centigrade, unless otherwise mentioned.

Example 1..Preparation of 8-hydroxy-2-methylisoquinolinium iodide A solution of 3.63 g. of 8-isoquinolinol and 4 ml. of methyl iodide in 50 ml. of ethanolwas stirred at reflux temperature for 8 hours, cooled and filtered to give, after recrystallization from ethanol-ethyl acetate, 8-hydroxy-2- methylisoquinolinium iodide, having a melting point of 220-221.

Example 2.Preparation of 2-methyl-1,2,3,4-tetrahydro- 8-isoquinolin0l A solution of 2.87 g. of 8-hydroxy-2-methylisoquinolinium iodide in 200 ml. of ethanol was hydrogenated over platinum oxide at room temperature and at 50 p.s.i. pressure. The catalyst was removed by filtration and the filtrate was evaporated to dryness. The residue was'dis solved in 100 ml. of methanol and treated with 516.5 mg. of sodium methylate in methanol. The solvent was evaporated under reduced pressure, and the solid residue was extracted with boiling methylene chloride. The .extract was evaporated to dryness to yield 1.6 g. of 2-methyl- 1,2,3,4-tetrahydro-8-isoquinolinol, M.P. 170-173.5.

anol-ether to yield 2.97 g. of S-methoxy 2 methylisoquinolinium iodide as yellow crystals, M.P. 231-232".

Example 4.--Preparation of 8-methoxy 2 methyl-1,2,

3,4-tetrahydroisoquinoline hydrochloride from 2-methyl-1,2,3,4-tetrahydro-8-isoquinolinol 689 mg. of 2-methyl-1,2,3,4-tetrahydro-8-isoquin0linol were dissolved in 150 ml. of benzene. After the addition of 764 mg. of phenyltrimethylammonium chloride and 4.45 ml. of 1 N sodium hydroxide, the solution was heated at reflux temperature for 8 hours. The water formed during the reaction was collected in a Dean-Stark trap. The reaction mixture was cooled, washed with dilute sodium hydroxide and then with water. After the addition of water to the organic phase, the resulting two phase mixture was stirred vigorously and adjusted to pH 6.0 with 1 N hydrochloric acid. The aqueous acid layer was made strongly alkaline with 1 N sodium hydroxide and extracted with methylene chloride. The organic layer was washed with water, dried with sodium sulfate and evaporated to dryness to yield 503 mg. of liquid 8-methoxy-2- methyl-1,2,3,4-tetrahydroisoquinoline. This material was dissolved in 25 ml. of methanol, and the solution was made strongly acidic with ethanolic hydrogen chloride and evaporated to dryness. The residue was recrystallizedfrom methanol-ether, yielding 310 mg. of the hydrochloride of 8-methoxy-2-methyl-l,2,3,4-tetrahydroisoquinoline, M.P.

Example 5 .-Preparation of 8-methox'y-2-methyl-1,2,3,4- tetrahydroisoquinoline hydrochloride from 8-methoxy- 2-methylisoquinolinium iodide A solution containing 2 g. of 8-methoxy-2-methylisoquinolinium iodide in ethanol was hydrogenated over platinum oxide at room temperature and-at 50 p.s.i. pressure. The catalyst was removed by filtration, and-the filtrate was evaporated to dryness under reduced pressure to give 1.88 g. of the hydroiodide. This material was dissolved in 25 ml. of 1 N sodium hydroxide and the solution was extracted with methylene chloride. The organic layer was washed with water, dried with sodium sulfate, and evaporated under reduced pressure to give 1.09 g. of oil. An ethanolic solution of this material was treated with hydrogen chloride in ethanol, and then evaporated to dryness. The residue was crystallized from ethanol-ether .to give 1.13 g. of white crystalline 8-methoxy2-methyl- 1,2,3,4-tetrahydroisoquinoline hydrochloride, M.P.-215- 216.

Example 6 .--Preparation of 8-methoxyisoquinoline To a solution of 29 g. of S-isoquinolinol and 11.35 g. of sodium methylate in 175 ml. of methanol, 36.1 g. of phenyltrimethylammonium chloride were added. The mixture was stirred for one hour, filtered to remove the precipitated salt, and then evaporated under reduced pressure. The oily residue was dissolved in m1. of dimethylformamide. The solution was heated at reflux for two hours, cooled, and then evaporated. The residue was dissolved in 250 ml. of methylene chloride and extracted with 1 N sodium hydroxide solution. The aqueous layer was extracted with methylene chloride. The organic layer was then washed with water, dried with sodium sulfate, treated with charcoal, and evaporated to dryness to give 43.2 g. of dark oil. Dimethylaniline was removed from this materialby distillation at 58-89 C./ 17-18 mm., and the distillation residue wasfiltered through a column containing 10 g. of alumina'II. The column was eluted with ether, and after evaporation of the eluate 25.8 g. of light brown liquid was obtained. Crystallization from etherztsentsaln e gave 20.6 g. of pure 8-methoxyisoquinoline, M.P.

The corresponding hydrochloride salt was prepared as follows:

A solution of 21.86 g. S-methoxyisoquinoline in 125 ml. of methanol was acidified with ethanolic hydrogen chloride and evaporated to dryness to yield 26.8 g. of the hydrochloride salt of S-methoxyisoquinoline as a yellowish solid, M.P. -1705". Y

Example 7.Preparation of 8-methoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride Example 8. l reparation of 8-methoxy-3,4-

dihydroisoquinoline' A solution ofv 2.8 g. of 8-methoxy-1-,2,3,4-tetrahydroisoquinoline hydrochloride in 100ml. of methanol was neutralized with 756.5 mg. of sodium methylate in methanol. After evaporation of the solvent, the residue-was extracted with ether. Removal of the solvent gave 2.23 g. of 8-methoxy1,2,3,4-tetrahydroisoquinoline, which was dissolved in 75 ml. of methanol and stirred for 2 hours at room temperature with 6.12 ml. of a 16.6% sodium hypochlorite solution. After the addition of 6.92 g. of sodium hydroxide pellets, the reaction mixture was refluxed for 2 hours, and then evaporated to dryness. The residue was mixed with water and extracted with methylene chloride. The organic layer was washed with water, dried with sodium sulfate, treated with charcoal, and evaporated to dryness. The liquid residue was dissolved in ether, treated with Dry Ice, filtered, and then evaporated to yield 2.1 g. of 8-methoxy-3,4-dihydroisoquinoline as an oil.

The hydrochloride salt was prepared as follows:

A solution of 377 mg. of 8-methoxy-3,4-dihydroisoquinoline in 25 ml. of methanol was treated with charcoal, and acidified with ethanolic hydrogen chloride. Removal of the solvent yielded 461 mg. of crude hydrochloride, which was crystallized from methanol-benzene and then from methylene chloride-ether to give 238 mg. of 8-methoxy-3,4-dihydroisoquinoline hydrochloride as pale yellow crystals, M.P. 175175.5.

Example 9.-Preparation of 8-methoxy-2-methyl-3,4- dihydroisoquinolinium iodide A solution of 8.0 g. of 8-methoxy-3,4-dihydroisoquino line in 250 ml. of benzene was stirred with 15 ml. of methyl iodide for 65 hours at room temperature. The reaction mixture was chilled. The solid that formed was collected by filtration and crystallized from methanolether to give 12.4 g. of yellow crystalline 8-methoxy-2- methyl-3,4-dihydroisoquinolinum iodide, M.P. 182- 182.5".

Example 10.Preparation of 8-methoxy-1,2-dimethyll,2,3,4-tetrahydroisoquinoline hydrochloride To a concentrated ether solution of methylmagnesium iodide, prepared from 6.52 g. of magnesium and 16.7 ml. of methyl iodide, 8.12 g. of 8-methoxy-2-methyl3,4- dihydroisoquinolinium iodide were added in small portions. The mixture was refluxed for 1.5 hours, cooled, decomposed with a saturated aqueous sodium sulfate solution, and then diluted with 200 ml. of water. The aqueous mixture was extracted with ether. The ether phase was washed with water, dried with sodium sulfate, treated with charcoal, filtered and evaporated to give 3.82 g. of 8-methoxy-l,Z-dimethyl l,2,-3,4-tetrahydroisoquinoline. A solution of 535 mg. of this material in 25 ml. of ethanol was acidified with ethanolic hydrogen chloride and evap orated to dryness. The residue was crystallized from methylene chloride-ether to yield 529 mg. of 8-methoxy- 1,2-dimethyl-1,2,3,4-tetrahydroisoquinoline hydrochloride, M.P. 159.5-161.5.

Example l1.Preparation of 8-ethoxy-2-ethyl-l,2,3,4- tetrahydroisoquinoline hydrochloride A solution of 4.0 g. of 8-isoquinolinol in 100 ml. of ethanol was mixed with 1.635 g. of sodium methylate, heated to reflux temperature, and treated with ml. of ethyl iodide. The mixture was stirred at reflux temperature for 16 hours, concentrated to about 50 ml. and chilled. Filtration of the reaction mixture yielded 5.42 g. of yellow solid material, which was crystallized from methanol-ether to give 3.84 g. of 8-ethoxy-2-ethylisoquinolinium iodide, M.P. 175210.

A solution of 3.3 g. of this material in 60 ml. of 50% aqueous isopropanol was stirred during the gradual addition of 1.3 g. of sodium borohydride (over a 10 minute period). The mixture was stirred for 3 hours and then evaporated under reduced pressure. The residue was suspended in 1 N sodium hydroxide and the suspension was extracted with ether. The organic layer was washed with water, dried with sodium sulfate and evaporated to give 824 mg. of 8-ethoxy-2-ethyl-1,2,3,4-tetrahydroisoquinoline. An ethereal solution of this base was acidified with ethanolic hydrogen chloride and then evaporated. The residue was crystallized from methanol-ether to give 780 mg.

10 of the white, crystalline 8-ethoxy-2-ethyl-1,2,3,4-tetrahydroisoquinoline hydrochloride, M.P. 206.5-207".

Example 12.Preparation of 2-ethyl-8-methoxyisoquinolinium iodide A solution of 4.0 g. of S-methoxyisoquinoline and 6.0 ml. of ethyl iodide in 50 ml. of ethanol was heated for 8 hours at reflux temperature and chilled. The precipitate was removed by filtration to give 6.3 g. of yellow powder, M.P. 205208, which was crystallized from methanolether to yield 5.6 g. of bright yellow crystalline 2-ethyl-8- methoxy isoquinolim'um iodide, M.P. 209-2095".

Example 13.-.-Preparation of 2-ethyl-8-methoxy-1,2,3,4- tetrahydroisoquinoline hydrochloride A solution of 5.11 g. of 2ethy1-8-methoxy-isoquinolinium iodide in 100 ml. of 50% aqueous isopropanol was stirred during the gradual addition of 2.31 g. of sodium borohydride (over a 10-minute period). After 4 hours of stirring at room temperature, the mixture was evaporated under reduced pressure. The residue was treated with 50 ml. of water, and the mixture was extracted with methylene chloride. The organic layer was washed with water,

. dried with sodium sulfate and evaporated to give 3.1 g.

of crude liquid 2-ethyl-8-methoxy-1,2,3,4-tetrahydroisoquinoline. A solution of this material in ethanol was acidified with ethanolic hydrogen chloride and evaporated, yielding 3.37 g. of solid which was crystallized from methanol-ether to give 2.39 g. of the 2-ethyl-8-methoxy-1,2,3,4- tetrahydroisoquinoline hydrochloride, M.P. 195-1955 Example 14.-Capsule formulation Per capsule, mg.

8-methoxy-2-methyl 1,2,3,4, tetrahydroisoquinoline hydrochloride 25 Lactose 158 Corn Starch 37 Talc 5 Total weight 225 Procedure: 25 parts of 8-methoxy-2-methyl-1,2,3,4- tetrahydroisoquinoline hydrochloride were mixed with 158 parts of lactose and 37 parts of corn starch in a suitable mixer. The mixture was further blended by passing through a Fitzpatrick Comminuting Machine with a No. 1A screen with knives forward. The blended powder was returned to the mixer and 5 parts of talc were added and blended thoroughly. The mixture was then filled into No. 4 hard shell gelatin capsules on a Parke Davis capsulating machine.

Example l5.Capsule formulation Per capsule, mg.

8-methoxy-2-methyl 1,2,3,4 tetrahydroisoquinoline hydrochloride 50 Lactose, U.S.P Corn starch, U.S.P 30 Talc, U.S.P. 5

Total weight 210 Example 16.-Tablet formulation Per tablet, mg. 8-methoxy 1,2,3,4 tetrahydroisoquinoline hydro- Procedure: 10 parts of 8- methoxy-1,2,3,4-tetrahydrisoquinoline hydrochloride were mixed with 113.5 parts of lactose, 70.5 parts of corn starch and 8 parts of pregelatinized corn starch in a suitable size mixer. The mix was passed through a Fitzpatrick Comminuting Machine fitted with No. 1A screen with knives forward. Thereafter, the mix was returned to the mixer and moistened with water to a thick paste. The moist mass was passed through a No. 12 screen and the moist granules were dried on a paper-lined trays. The dried granules were returned to the mixer, 3 parts of calcium stearate were added and mixed well. The granules were compressed at a tablet weight of 200 mg. using standard concave punches having a diameter of Example l7.--Parenteral formulation 'Each 1 cc. ampul contains:

8-methoxy 2 methyl-'1,2,3,4-tetrahydro-isoquinoline- 11.02 mg. (2% excess) Methyl Paraben, U .S.P.-1.8 mg.

Propyl Paraben, U.S.P.-0.'2 mg.

Water for injection, -U.S.P. q.s. ad 1 cc.

Procedure (for 10,000 cc.): In a clean glass or glasslined vessel, 8,000 cc. of Water for injection were heated to 90 and then cooled to 50-60". Thereafter, 18 grams of methyl paraben and 2 grams of propyl paraben were added and dissolved with stirring. The solution was allowed to cool to room temperature. 10.20 grams of 8- methoxy-Zunethyl 1, 2,3,4 tetrahydroisoquinoline were added under an atmosphere of nitrogen and stirred until completely dissolved. Sufiicient water for injection was then added to make a total volume of 10,000 cc. This solution was filtered through an 02 Selas candle, filled into suitable size ampuls, gassed with nitrogen and sealed. The ampuls were autoclaved at 10 lbs. p.'s.i. for 30 minutes.

We claim:

1. A compound of the formula N lower alkyl wherein R is lower alkyl and X- is selected fromthe group consisting of iodine, cholrine and bromine.

2. A compound in accordance with claim 1, 8- methoxy-Z-methylisoquinolinium iodide.

3. A compound in accordance with claim 1, 8- methoxy-2-ethylisoquinolinium iodide.

4. 8-methoxy 2 methyl-3,4-dihydro-isoquinolinium iodide.

References Cited UNITED STATES PATENTS 3,101,338 '8/1963 Robinson 260-289 X 3,117,970 1/19 64 Weisbach 2'60-286 3,227,720 'l/ 1966 Brossi 260289 3,457,266 7/19'69 Gibas 260-289 3,466,289 9/1969 Osbond 260-28 9 X 3,475,538 10/1969 Mathi'son 2'60'2'86 Q 3,562,280 2/l 971 Leimgruber et a1. 2'60289 DONALD D. DAUS, Primary Examiner 

